ID   MT-3 [Human contaminated breast cancer]
AC   CVCL_2129
SY   MT3
DR   CLO; CLO_0007890
DR   EFO; EFO_0002241
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03472975
DR   BioSample; SAMN03473582
DR   BioSample; SAMN06481118
DR   cancercelllines; CVCL_2129
DR   DSMZ; ACC-403
DR   DSMZCellDive; ACC-403
DR   EGA; EGAS00001000610
DR   GEO; GSM115102
DR   GEO; GSM217592
DR   GEO; GSM412073
DR   GEO; GSM412084
DR   GEO; GSM412093
DR   GEO; GSM412098
DR   GEO; GSM412106
DR   GEO; GSM412110
DR   GEO; GSM459700
DR   GEO; GSM474280
DR   GEO; GSM474281
DR   GEO; GSM476484
DR   GEO; GSM476485
DR   GEO; GSM478311
DR   GEO; GSM478312
DR   GEO; GSM478314
DR   GEO; GSM478315
DR   GEO; GSM478320
DR   GEO; GSM478321
DR   GEO; GSM783977
DR   GEO; GSM847419
DR   GEO; GSM847498
DR   GEO; GSM844610
DR   GEO; GSM1172986
DR   IGRhCellID; MT3
DR   LINCS_HMS; 50031
DR   PharmacoDB; MT3_969_2019
DR   Progenetix; CVCL_2129
DR   Wikidata; Q54906937
RX   PubMed=1446057;
RX   PubMed=9150904;
RX   PubMed=11044355;
RX   PubMed=12661003;
RX   PubMed=12800145;
RX   PubMed=15677628;
RX   PubMed=20215515;
RX   PubMed=24176112;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=28196595;
CC   Problematic cell line: Contaminated. Shown to be a LS174T derivative (PubMed=25877200; DSMZ). Originally thought to originate from a breast carcinoma.
CC   Part of: MD Anderson Cell Lines Project.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00506.
CC   Population: Caucasian.
CC   Doubling time: 37.1 +- 8.1 hours (PubMed=9150904); ~30 hours (DSMZ=ACC-403).
CC   HLA typing: A*02:01,02:01; B*07:17,15:50; C*04:01,06:02 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI) (PubMed=12661003; PubMed=15677628).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: DSMZ; ACC-403; true.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
CC   Cell type: Epithelial cell of colon; CL=CL_0011108.
ST   Source(s): DSMZ=ACC-403; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D13S317: 10,11
ST   D16S539: 11,13
ST   D18S51: 10,12
ST   D19S433: 13,14
ST   D21S11: 29,31
ST   D2S1338: 18,22
ST   D3S1358: 15,16
ST   D5S818: 12,17 (DSMZ=ACC-403)
ST   D5S818: 12 (PubMed=25877200)
ST   D7S820: 10.3,11,12
ST   D8S1179: 12,15 (PubMed=25877200)
ST   D8S1179: 13,15 (DSMZ=ACC-403)
ST   FGA: 20,21
ST   Penta D: 9,10
ST   Penta E: 13,15 (PubMed=25877200)
ST   Penta E: 13,15,17,21 (DSMZ=ACC-403)
ST   TH01: 6,7
ST   TPOX: 8,9
ST   vWA: 13,14,16,17 (DSMZ=ACC-403)
ST   vWA: 14,17 (PubMed=25877200)
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1384 ! LS174T
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 34
RX   PubMed=1446057; DOI=10.1007/BF01831480;
RA   Naundorf H., Rewasowa E.C., Fichtner I., Buttner B., Becker M.,
RA   Gorlich M.;
RT   "Characterization of two human mammary carcinomas, MT-1 and MT-3,
RT   suitable for in vivo testing of ether lipids and their derivatives.";
RL   Breast Cancer Res. Treat. 23:87-95(1992).
RX   PubMed=9150904; DOI=10.1023/A:1005756632293;
RA   Hambly R.J., Double J.A., Thompson M.J., Bibby M.C.;
RT   "Establishment and characterisation of new cell lines from human
RT   breast tumours initially established as tumour xenografts in NMRI nude
RT   mice.";
RL   Breast Cancer Res. Treat. 43:247-258(1997).
RX   PubMed=11044355; DOI=10.1054/bjoc.2000.1458;
RA   Davidson J.M., Gorringe K.L., Chin S.-F., Orsetti B., Besret C.,
RA   Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.;
RT   "Molecular cytogenetic analysis of breast cancer cell lines.";
RL   Br. J. Cancer 83:1309-1317(2000).
RX   PubMed=12661003; DOI=10.1002/gcc.10196;
RA   Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U.,
RA   Santibanez-Koref M.F., Schlag P.M., Scherneck S.;
RT   "Identification of microsatellite instability and mismatch repair gene
RT   mutations in breast cancer cell lines.";
RL   Genes Chromosomes Cancer 37:29-35(2003).
RX   PubMed=12800145; DOI=10.1002/gcc.10218;
RA   Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B.,
RA   Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A.,
RA   Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D.,
RA   Edwards P.A.W., Chaffanet M.;
RT   "A recurrent chromosome translocation breakpoint in breast and
RT   pancreatic cancer cell lines targets the neuregulin/NRG1 gene.";
RL   Genes Chromosomes Cancer 37:333-345(2003).
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).